The Magpie Trial: Effects of Magnesium Sulphate on Children at 18 Months
Author Information
Author(s): Magpie Trial Follow-Up Study Collaborative Group
Hypothesis
Does in utero exposure to magnesium sulphate for pre-eclampsia affect the child's chance of surviving without major neurosensory disability?
Conclusion
Magnesium sulphate for pre-eclampsia was not associated with a clear difference in the risk of death or disability for children at 18 months.
Supporting Evidence
- Of those allocated magnesium sulphate, 15.0% had death or neurosensory disability at 18 months.
- Children exposed to magnesium sulphate did not show a significant difference in risk of neurosensory disability compared to placebo.
- 73% of children included in follow-up were contacted.
Takeaway
This study looked at children whose mothers took magnesium sulphate during pregnancy. It found that it didn't really change the chances of the children being healthy or having problems at 18 months old.
Methodology
Children were assessed at 18 months using questionnaires, interviews, and neurodevelopmental testing.
Potential Biases
There was a risk of bias in follow-up due to difficulties in contacting families, especially in high PNM countries.
Limitations
Some children could not be followed up, and the study had less power than the original trial due to not including all children randomised.
Participant Demographics
Children were born to women with pre-eclampsia from 125 centres in 19 countries.
Statistical Information
Confidence Interval
95% CI 0.90–1.25
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website